Prognostic Value of Transcranial Doppler Ultrasound in the Clinical Evolution of Patients With Ac… (NCT07004790) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Prognostic Value of Transcranial Doppler Ultrasound in the Clinical Evolution of Patients With Acute Ischemic Stroke. The TRADE-AIS Study
50 participantsStarted 2026-08-01
Plain-language summary
This prospective observational study aims to determine whether specific parameters measured by transcranial Doppler ultrasound (TCD) can predict clinical outcomes in patients with acute ischemic stroke (AIS). The primary objective is to evaluate the association between middle cerebral artery (MCA) flow velocities and short-term neurological improvement. Secondary outcomes include the presence of collateral flow and flow patterns in relation to functional recovery measured by NIHSS and modified Rankin Scale (mRS) scores.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years
* Clinical diagnosis of acute ischemic stroke
* Onset of symptoms ≤ 24 hours before admission
* Underwent or will undergo transcranial Doppler ultrasound within 24 hours of symptom onset
* Able to provide informed consent or consent obtained from a legal representative
Exclusion Criteria:
* Evidence of intracerebral hemorrhage on imaging
* Inadequate temporal acoustic window for transcranial Doppler
* Intubated or hemodynamically unstable prior to Doppler evaluation
* Known diagnosis of neurodegenerative disease significantly affecting baseline neurological function (e.g., advanced dementia, Parkinson's disease)
* Refusal to participate or withdrawal of consent
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in NIHSS score from baseline to 72 hours
Timeframe: 72 hours
Trial details
NCT IDNCT07004790
SponsorJose Ivan Rodriguez de Molina Serrano
Sponsor typeOTHER
Study typeINTERVENTIONAL
Primary completion2027-07-31
Contact for this trial
JOSE IVAN RODRIGUEZ DE MOLINA SERRANO, MD, MSc, Ph, Crit Care sp